127 related articles for article (PubMed ID: 36946179)
1. Impact of adverse drug reactions on the treatment pathways of early rheumatoid arthritis patients: a prospective observational cohort study.
Velthuis K; Poppelaars F; Ten Klooster PM; Vonkeman HE; Jessurun NT
Expert Opin Drug Saf; 2023; 22(8):753-762. PubMed ID: 36946179
[TBL] [Abstract][Full Text] [Related]
2. Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions.
Abasolo L; Leon L; Rodriguez-Rodriguez L; Tobias A; Rosales Z; Maria Leal J; Castaño V; Vadillo C; Macarron P; Fontsere O; Jover JA
Semin Arthritis Rheum; 2015 Apr; 44(5):506-513. PubMed ID: 25532946
[TBL] [Abstract][Full Text] [Related]
3. First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept.
Velthuis K; Jessurun NT; Nguyen TDM; Scholl J; Jansen JRG; van Lint JA; Kosse LJ; Ten Klooster PM; Vonkeman HE
Expert Opin Drug Saf; 2023; 22(6):485-492. PubMed ID: 36683590
[TBL] [Abstract][Full Text] [Related]
4. Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients.
Giraud EL; Jessurun NT; van Hunsel FPAM; van Puijenbroek EP; van Tubergen A; Ten Klooster PM; Vonkeman HE
Expert Opin Drug Saf; 2020 Dec; 19(12):1617-1624. PubMed ID: 32990050
[TBL] [Abstract][Full Text] [Related]
5. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.
Leon L; Gomez A; Vadillo C; Pato E; Rodriguez-Rodriguez L; Jover JA; Abasolo L
Clin Exp Rheumatol; 2018; 36(1):29-35. PubMed ID: 28598787
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study.
Mimori T; Harigai M; Atsumi T; Fujii T; Kuwana M; Matsuno H; Momohara S; Takei S; Tamura N; Takasaki Y; Yamamoto K; Ikeuchi S; Kushimoto S; Koike T
Mod Rheumatol; 2019 Mar; 29(2):314-323. PubMed ID: 29611761
[TBL] [Abstract][Full Text] [Related]
7. Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Machado-Alba JE; Ruiz AF; Machado-Duque ME
Rev Panam Salud Publica; 2014 Dec; 36(6):396-401. PubMed ID: 25711751
[TBL] [Abstract][Full Text] [Related]
8. Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.
Mittal N; Sharma A; Jose V; Mittal R; Wanchu A; Bambery P
Rheumatol Int; 2012 Mar; 32(3):743-8. PubMed ID: 21161534
[TBL] [Abstract][Full Text] [Related]
9. An Analysis of Real-World Data on the Safety of Etanercept in Older Patients with Rheumatoid Arthritis.
Edwards CJ; Bukowski JF; Burns SM; Jones HE; Pedersen R; Sopczynski J; Marshall L
Drugs Aging; 2020 Jan; 37(1):35-41. PubMed ID: 31712995
[TBL] [Abstract][Full Text] [Related]
10. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.
Singh JA; Cameron DR
J Manag Care Pharm; 2012 May; 18(4 Supp C):S1-18. PubMed ID: 22656072
[TBL] [Abstract][Full Text] [Related]
11. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts.
García-Doval I; Hernández MV; Vanaclocha F; Sellas A; de la Cueva P; Montero D;
Br J Dermatol; 2017 Mar; 176(3):643-649. PubMed ID: 27258623
[TBL] [Abstract][Full Text] [Related]
12. [The importance of patient perspective in drug surveillance systems].
Gäwert L; Hierse F; Zink A; Strangfeld A
Z Rheumatol; 2010 Nov; 69(9):795-802. PubMed ID: 21063828
[TBL] [Abstract][Full Text] [Related]
13. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort.
Mueller RB; Kaegi T; Finckh A; Haile SR; Schulze-Koops H; von Kempis J;
Rheumatology (Oxford); 2014 Apr; 53(4):671-7. PubMed ID: 24352338
[TBL] [Abstract][Full Text] [Related]
14. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of gastrointestinal and hepatic adverse drug reactions in the treatment of rheumatoid arthritis with biomedical combination therapy and Chinese medicine.
Jiang M; Zha Q; He Y; Lu A
J Ethnopharmacol; 2012 Jun; 141(2):615-21. PubMed ID: 21782923
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?
Wabe N; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Hall C; Spargo L; Metcalf R; Proudman SM; Wiese MD
Int J Clin Pract; 2016 Apr; 70(4):340-50. PubMed ID: 26987888
[TBL] [Abstract][Full Text] [Related]
17. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.
Koike T; Harigai M; Ishiguro N; Inokuma S; Takei S; Takeuchi T; Yamanaka H; Tanaka Y
Mod Rheumatol; 2012 Aug; 22(4):498-508. PubMed ID: 21993918
[TBL] [Abstract][Full Text] [Related]
19. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice.
Grove ML; Hassell AB; Hay EM; Shadforth MF
QJM; 2001 Jun; 94(6):309-19. PubMed ID: 11391029
[TBL] [Abstract][Full Text] [Related]
20. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
